After last week's five deals, January finished the month with 12 pricings, making it the second most active January in the past decade, trailing only the 15 pricings in January 2006. Though pricings to start the year could signal healthy deal flow in...read more
KaloBios Pharmaceuticals, which is developing monoclonal antibodies to treat respiratory diseases and cancer, raised $70 million by offering 8.8 million shares (500,000 more than expected) at $8, the low end of the revised range of $8 to $9. The company will...read more
KaloBios Pharmaceuticals, which is developing monoclonal antibodies to treat respiratory diseases and cancer, revised the proposed deal size for its upcoming IPO on Wednesday. The South San Francisco, CA-based company now plans to raise $70 million by offering 8...read more
Weekly Recap: Most January pricings since 2006, Zoetis surges in debut
After last week's five deals, January finished the month with 12 pricings, making it the second most active January in the past decade, trailing only the 15 pricings in January 2006. Though pricings to start the year could signal healthy deal flow in...read more
KaloBios prices upsized deal at $8, at low end of the range
KaloBios Pharmaceuticals, which is developing monoclonal antibodies to treat respiratory diseases and cancer, raised $70 million by offering 8.8 million shares (500,000 more than expected) at $8, the low end of the revised range of $8 to $9. The company will...read more
KaloBios revises IPO terms; lowers range, increases shares offered
KaloBios Pharmaceuticals, which is developing monoclonal antibodies to treat respiratory diseases and cancer, revised the proposed deal size for its upcoming IPO on Wednesday. The South San Francisco, CA-based company now plans to raise $70 million by offering 8...read more
5 US IPOs planned for the week of Jan 28
The following IPOs are expected to price this week: Gladstone Land (LAND), an externally managed REIT planning to acquire agricultural real estate, plans to raise $50...read more